Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,800
Closed -$44.8K 268
2025
Q4
$44.8K Buy
+1,800
New +$45.4K 0.01% 186
2025
Q1
Sell
-333
Closed -$8.83K 240
2024
Q4
$8.83K Buy
+333
New +$9.03K ﹤0.01% 228
2024
Q1
Sell
-45,290
Closed -$1.3M 105
2023
Q4
$1.3M Sell
45,290
-11,442
-20% -$346K 0.53% 52
2023
Q3
$1.88M Sell
56,732
-1,067
-2% -$37.7K 0.82% 44
2023
Q2
$2.12M Buy
57,799
+4,589
+9% +$179K 0.91% 44
2023
Q1
$2.17M Buy
53,210
+679
+1% +$29.3K 1% 42
2022
Q4
$2.69M Buy
52,531
+2,903
+6% +$139K 1.3% 29
2022
Q3
$2.17M Buy
49,628
+236
+0.5% +$11.5K 1.14% 30
2022
Q2
$2.59M Buy
49,392
+1,520
+3% +$77.5K 1.31% 27
2022
Q1
$2.48M Buy
47,872
+232
+0.5% +$12K 1.09% 31
2021
Q4
$2.81M Sell
47,640
-668
-1% -$33.1K 1.2% 31
2021
Q3
$2.08M Buy
48,308
+1,548
+3% +$68.6K 0.9% 38
2021
Q2
$1.83M Buy
46,760
+1,778
+4% +$69.1K 0.77% 42
2021
Q1
$1.63M Buy
44,982
+4,142
+10% +$147K 0.76% 46
2020
Q4
$1.5M Buy
40,840
+1,377
+3% +$50.5K 0.78% 43
2020
Q3
$1.37M Buy
39,463
+9,468
+32% +$332K 0.79% 42
2020
Q2
$931K Buy
29,995
+12,097
+68% +$411K 0.61% 45
2020
Q1
$554K Buy
17,898
+3,440
+24% +$117K 0.51% 34
2019
Q4
$537K Buy
+14,458
New +$515K 0.42% 43

Other funds holding PFE

Modus Advisors's PFE Position: Q1 2026 in Review

Modus Advisors sold out of Pfizer (PFE) in Q1 2026, closing a stake of 1,800 shares — an estimated $44.8K sold.

Modus Advisors first reported a position in PFE in Q4 2019 and held it in 19 quarters. The position peaked at $2.81M in Q4 2021. 2,952 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Modus Advisors reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Modus Advisors sold 1,800 Pfizer shares in Q1 2026, an estimated $44.8K.
  • Modus Advisors first reported a position in Pfizer in Q4 2019 and held it in 19 quarters.
  • Modus Advisors's Pfizer position peaked at $2.81M in Q4 2021.
  • 2,952 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Modus Advisors's 13F filing for Q1 2026, filed 4 May 2026.